Glioblastoma Survival Rate
Researchers are continually working to improve the glioblastoma survival rate. Patients have a wider range of treatment options than ever before, and new therapies are being introduced on a regular basis. Additionally, clinical studies are providing better insight into how different cancers and cell types respond to treatment, allowing oncologists to recommend more effective therapies for each patient. For instance, researchers have identified a specific protein that makes glioblastomas less responsive to a commonly prescribed chemotherapy drug; oncologists can test patients for this protein to determine if a different medication might be more effective before treatment even begins.
Ongoing advancements in individualized medicine are likely to have a significant impact on the glioblastoma survival rate moving forward. In recent years, researchers have observed improved survival rates in patients who:
- Undergo surgery to remove at least 90 percent of the tumor
- Receive radiation therapy combined with the chemotherapy drug temozolomide
- Access novel experimental therapies, such as immunotherapies, biological therapies and vaccine therapies, through clinical trials
To help patients achieve the best possible outcomes in terms of both survival and quality of life, Moffitt Cancer Center takes a comprehensive, individualized approach to treatment. A collaborative team of oncologists evaluates each patient’s diagnosis to determine which options offer the most promise, and supportive care services are available in the same convenient location. Additionally, our Neuro-Oncology Program exclusively treats cancers of the brain and spine. This allows patients to obtain highly specialized medical attention from some of the most experienced oncologists in the field.
Referrals are not required to make an appointment with the experts in Moffitt Cancer Center’s Neuro-Oncology Program. For more information about the glioblastoma survival rate, call 1-888-MOFFITT or submit a new patient registration form online.